Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with alirocumab
results in greater change from baseline in intracranial atherosclerotic plaque at week 26
than control in adults with acute ischemic stroke from intracranial atherosclerosis taking
lipid lowering therapy.